Tag: DurAVR transcatheter heart valve
$38.5M investment to expand Anteris’ manufacturing capacity, global clinical program
Anteris Technologies Global Corp has announced a binding agreement for a private placement valued at approximately AUD 38.5 million (USD 25.2 million) to support the advancement of its PARADIGM clinical trial and accelerate global commercialisation efforts.
Anteris granted utility patent for heart valve replacement technology
Australian biotechnology company Anteris Technologies announced that the United States Patent and Trademark Office has issued a utility patent for its novel DurAVR transcatheter heart valve (THV).
Featured Article
“New Starts Here”: AGHA launches national platform for gift and homewares
Australia’s peak organisation for the gift and homewares sector, the Australian Gift & Homewares Association (AGHA), has revealed plans for a major expansion in 2026, introducing Gifted Melbourne 2026 to complement the long-established AGHA Sydney Gift Fair.
